Table 4. Best overall response and clinical benefit, evaluable patients (part 2).
| Investigator assessment, n (%) | Group Aa (n=68) | Group Bb (n=31) | All patients (n=99) |
|---|---|---|---|
| Overall response rate (95% CI) | 48 (71) (58.3–81.0) | 24 (77) (58.9–90.4) | 72 (73) (62.9–81.2) |
| Complete response | 6 (9) | 1 (3) | 7 (7) |
| Partial response | 42 (62) | 23 (74) | 65 (66) |
| Clinical benefit ratec |
56 (82) |
25 (81) |
81 (82) |
|
Stable disease | |||
| <24 Weeks | 6 (9) | 3 (10) | 9 (9) |
| ⩾24 Weeks | 8 (12) | 1 (3) | 9 (9) |
| Progressive disease | 3 (4) | 3 (10) | 6 (6) |
| Not determined | 3 (4) | 0 | 3 (3) |
Abbreviation: CI=confidence interval.
a
Group A allowed ⩽1 prior cytotoxic chemotherapy regimen for metastatic disease.
b
Group B allowed ⩽3 prior cytotoxic chemotherapy regimens for metastatic disease, with prior lapatinib permitted.
c
Clinical benefit rate=complete response+partial response+stable disease ⩾24 weeks.